Implied FYX Analyst Target Price: $122

Analysts project a 12.46% upside for the First Trust Small Cap Core AlphaDEX Fund ETF (FYX), with an implied 12-month target price of $121.97 based on the weighted average analyst targets of its underlying holdings. This potential growth is significantly influenced by key constituents such as Harrow Inc (HROW), Travere Therapeutics Inc (TVTX), and Omnicell Inc (OMCL), which individually show substantial analyst target upsides of 56.48%, 53.10%, and 39.49% respectively. While these figures suggest considerable potential, the report highlights the need for further investor research to validate the justification of these analyst targets.

Analysis

An analysis of the First Trust Small Cap Core AlphaDEX Fund ETF (FYX) reveals a potential 12.46% upside, based on a weighted average implied analyst target of $121.97 per unit against its recent trading price of $108.45. This optimistic forecast is significantly driven by a few underlying holdings with substantial perceived growth potential. Specifically, Harrow Inc (HROW), Travere Therapeutics Inc (TVTX), and Omnicell Inc (OMCL) exhibit analyst target upsides of 56.48%, 53.10%, and 39.49%, respectively. Despite these bullish individual targets, the overall tone of the report is cautious, as reflected by a mixed sentiment score of 0.15. The analysis explicitly questions whether these high price targets are justified or merely relics of past optimism, suggesting a risk of future downgrades if company or industry developments do not support them. This highlights a divergence between high bottom-up analyst conviction on certain small-cap healthcare stocks and a more circumspect view on the achievability of these targets, demanding further due diligence from investors.

Key Decisions for Investors

• Investors could view FYX as a vehicle for small-cap exposure, but must acknowledge that its projected 12.46% upside is heavily concentrated in a few holdings with highly optimistic and unverified analyst targets.
• It is critical to conduct fundamental due diligence on the key drivers—Harrow (HROW), Travere Therapeutics (TVTX), and Omnicell (OMCL)—to validate the bullish analyst assumptions before considering a direct investment.
• Investors should monitor these specific holdings for any potential analyst target price downgrades, as this could serve as a leading indicator of weakening fundamentals and disproportionately impact the ETF's performance.